Developed Formulas
  • Supports reduction of mucosal inflammation

  • Helps protect and restore the intestinal barrier function

  • Counteracts gut dysbiosis

  • Produces GABA neurotransmitter

  • Reduces pain associated with IBS

Ready to market
Clinical test
In vitro test
Hydrosoluble powder
Allergen Free
Real time stability

Bifidobacterium breve BR03 (DSM 16604)

Lactiplantibacillus plantarum LP01 (LMG P-21021)

Label Claim
Effective nutraceutical combination
Scientific Rationale

Irritable Bowel Syndrome (IBS) is a widespread functional bowel disorder, affecting approximately 5% of the global population at any given time, with variations in prevalence across different countries [1]. Characterized by abdominal pain, bloating, and alterations in bowel function, the exact causes and mechanisms of IBS are not fully understood. However, current studies suggest that IBS is linked to changes in the gut microbiota, chronic low-grade mucosal inflammation, immune function disturbances, visceral hypersensitivity, altered gut-brain axis regulation, and psychosocial factors [2]. The gut-brain axis, particularly the GABAergic system, is a critical element in IBS, and due to diminished levels of GABA in IBS patients, GABA-analogous medications are being explored for reducing visceral pain [3].

BIFICOL® incorporates two of Probiotical’s leading anti-inflammatory bacterial strains, chosen for their impact on immune function, mucosal inflammation, gut dysbiosis, and GABA production : Lactiplantibacillus plantarum LP01 and Bifidobacterium breve BR03 [4-6]. These strains have shown significant effectiveness in supporting the treatment and prevention of gastrointestinal inflammatory disorders and reducing bacterial overgrowth in IBS by promoting a Th2- and counteracting Th1-immune response [6-12].

  • LP01 and BR03 can directly antagonize specific potential nosocomial pathogens, including Klebsiella pneumoniae, E. coli, Staphylococcus aureus, Enterococcus faecium, and Pseudomonas aeruginosa [8].
  • LP01 has demonstrated protection of epithelial cells against inflammation-induced barrier dysfunction [6].
  • In an in vitro study, LP01 was found capable of producing GABA [9].

BIFICOL® is supported by three distinct clinical studies:

  • In the first trial, BIFICOL® significantly alleviated pain and the primary symptoms typically associated with IBS [10].
  • The other two clinical studies showed BIFICOL®'s effectiveness in improving evacuation disorders and abdominal bloating, as well as constipation and related symptoms, intestinal motility, and the frequency of bowel movements [11, 12].


1. Oka P, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. Doi: 10.1016/S2468-1253(20)30217-X

2. Sun JR, et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020 Mar- Apr;26(2):66-77. Doi: 10.4103/sjg.SJG_384_19

3. Gros M, et al. Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management. J Clin Med. 2021 July;10(15):3429. doi:10.3390/jcm10153429

4. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32

5. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47

6. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214

7. Magistrelli L, et al. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol. 2019 May 7;10:969. doi: 10.3389/fimmu.2019.00969

8. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

9. Internal Probiotical data

10. Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106. DOI: 10.1097/01.mcg.0000129271.98814.e2

11. Del Piano M. et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools. A double blind, randomized, placebo controlled study. J Clin Gastroenterol, 2010; 44(8):S30-34. doi:10.1097/MCG.0b013e3181ee31c3

12. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 separately). CIBUS, 2005; 1(1):23-30. doi:10.1097/MCG.0b013e3181ee31c3